Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;71(12):3093-3097.
doi: 10.1007/s00262-022-03208-2. Epub 2022 May 26.

Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study

Pascale Palassin #  1 , Alexandre T J Maria #  2   3 , Chayma Ladhari  1 , Xavier Quantin  4 , David Montani  5   6   7 , Arnaud Bourdin  8   9 , Clément Boissin  8 , Pierre Fesler  9   10 , Dominique Hillaire-Buys  1 , Philippe Guilpain #  2   3 , Jean-Luc Faillie #  11   12
Affiliations

Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study

Pascale Palassin et al. Cancer Immunol Immunother. 2022 Dec.

Abstract

Immune checkpoint inhibitors (ICI) restore immune response against cancer cells that can lead to immune-related adverse effects. While cardiovascular immune-related adverse effects are known to be associated with checkpoint inhibitors, recent case reports have raised concerns about the potential association with pulmonary hypertension (PH). By using the global pharmacovigilance database VigiBase, we investigated the onset of PH associated with ICI and propose a comprehensive description of the 42 cases of PH reported with ICI recorded in this database. Through this study and review of the cases published in the literature, we discuss the possible link between PH and ICI in the context of cancer in order to better understand this rare but potentially fatal event.

Keywords: Adverse drug reactions; Auto-immune disorders; Immune checkpoint inhibitors; Pharmacovigilance; Pulmonary hypertension.

PubMed Disclaimer

Conflict of interest statement

ATJM has received fees from Actelion and declares speaking fees from Astra-Zeneca, Sanofi-Aventis and BMS in the last 3 years. PG is a medical expert for LFB (Laboratoire Français du Biofractionnement) and has received fees from Abbvie, Actelion, Boehringer Ingelheim France, Bouchara-Recordati, Novartis, Pfizer, and Roche in the last 5 years. DM reports grants and personal fees from Actelion, grants and personal fees from Bayer, personal fees from GSK, personal fees from Pfizer, grants, personal fees and non-financial support from MSD, personal fees from Chiesi, personal fees from Boerhinger, non-financial support from Acceleron, outside the submitted work. PF has received travel and accommodation fees from Actelion, Johnson and Johnson, BMS, Pfizer and Servier in the last 5 years. Other authors declare that they have no conflicts of interest.

References

    1. Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, Monestier S, Grob J-J, Scemama U, Jacquier A, Lalevee N, Barraud J, Peyrol M, Laine M, Bonello L, Paganelli F, Cohen A, Barlesi F, Ederhy S, Thuny F. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136:2085–2087. doi: 10.1161/CIRCULATIONAHA.117.030571. - DOI - PubMed
    1. Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano J-P, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579–1589. doi: 10.1016/S1470-2045(18)30608-9. - DOI - PMC - PubMed
    1. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J. Am. Heart Assoc. 2020 doi: 10.1161/JAHA.119.013757. - DOI - PMC - PubMed
    1. Fournel L, Boudou-Rouquette P, Prieto M, Hervochon R, Guinet C, Arrondeau J, Alexandre J, Damotte D, Wislez M, Batteux F, Icard P, Goldwasser F, Alifano M. Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. Cancer Chemother Pharmacol. 2020;86:497–505. doi: 10.1007/s00280-020-04142-9. - DOI - PubMed
    1. Glick M, Baxter C, Lopez D, Mufti K, Sawada S, Lahm T. Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy. Pulm Circ. 2020;10:204589402096096. doi: 10.1177/2045894020960967. - DOI - PMC - PubMed

MeSH terms

Substances